[Clinical and laboratory criteria for assessing the efficacy of Essliver Forte for patients with combined liver and gall bladder pathologies].
As many as 60 patients with combined pathologies (chronic hepatitis (CH) and chronic non-calculous cholecystitis (CNCC)) were examined, and 20 healthy subjects were included in the control group. The efficacy of Essliver Forte for patients with chronic non-calculous cholecystitis combined with chronic hepatitises (both viral hepatitis and steatohepatitis) was assessed on the basis of clinical, biochemical and bacteriological criteria. Essliver Forte was found to improve the clinical and biochemical parameters of the functional liver condition, bile biochemical characteristics and intestinal microbiocenosis in patients with combined pathologies. The positive clinical effect is most evident for patients with chronic non-calculous cholecystitis and chronic steatohepatitis (both alcohol and non-alcohol). Essliver Forte can be recommended for treatment of patients with combined pathologies.
Kozlova
I V
IV
Antonian
A A
AA
Volkov
S V
SV
D042101:Acalculous Cholecystitis / Q000150:complications / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D001646:Bile / Q000737:chemistry; D001774:Blood Chemical Analysis; D002908:Chronic Disease; D005260:Female; D006521:Hepatitis, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000627:therapeutic use*; D016896:Treatment Outcome
D010743:Phospholipids